Abstract
Stroke is the second cause of death worldwide and one of the leading cause of disability. Due to the high rate of recurrence, in high risk-patients (eg patients affected by atherosclerotic vascular disease), long-term antiplatelet therapy reduces the risk of vascular events such as non-fatal myocardial infarction, non-fatal stroke, or vascular death. The percentage of reduction of the events can be estimated in approximately 25%. These data justify the directions that are given to us by the current guidelines for prevention of secondary stroke, which recommend the broad use of antiplatelet therapy both for the secondary prevention of stroke in patients with a history of non-cardioembolic stroke or TIA.
As for the primary prevention indications are less accurate because the absolute benefi ts of aspirin in reducing the happening of vascular events, are generally much lower than in secondary prevention.
Although several trials have been investigated use of antiplatelet drugs in ischemic stroke patients, ascertaining the sure benefit, especially in secondary prevention in non-cardioembolic stroke, various issues remains unclarified, and new questions raises with the analysis of the results of available trials.
Keywords: Antiplatelets, stroke, prevention.
Current Vascular Pharmacology
Title:Antiplatelets in Stroke Prevention
Volume: 11 Issue: 6
Author(s): Antonio Pinto, Domenico Di Raimondo, Antonino Tuttolomondo, Carmelo Butta and Giuseppe Licata
Affiliation:
Keywords: Antiplatelets, stroke, prevention.
Abstract: Stroke is the second cause of death worldwide and one of the leading cause of disability. Due to the high rate of recurrence, in high risk-patients (eg patients affected by atherosclerotic vascular disease), long-term antiplatelet therapy reduces the risk of vascular events such as non-fatal myocardial infarction, non-fatal stroke, or vascular death. The percentage of reduction of the events can be estimated in approximately 25%. These data justify the directions that are given to us by the current guidelines for prevention of secondary stroke, which recommend the broad use of antiplatelet therapy both for the secondary prevention of stroke in patients with a history of non-cardioembolic stroke or TIA.
As for the primary prevention indications are less accurate because the absolute benefi ts of aspirin in reducing the happening of vascular events, are generally much lower than in secondary prevention.
Although several trials have been investigated use of antiplatelet drugs in ischemic stroke patients, ascertaining the sure benefit, especially in secondary prevention in non-cardioembolic stroke, various issues remains unclarified, and new questions raises with the analysis of the results of available trials.
Export Options
About this article
Cite this article as:
Pinto Antonio, Raimondo Di Domenico, Tuttolomondo Antonino, Butta Carmelo and Licata Giuseppe, Antiplatelets in Stroke Prevention, Current Vascular Pharmacology 2013; 11 (6) . https://dx.doi.org/10.2174/157016111106140128112915
DOI https://dx.doi.org/10.2174/157016111106140128112915 |
Print ISSN 1570-1611 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6212 |
Call for Papers in Thematic Issues
Ischemic Cardiovascular Diseases: Mechanisms, Diagnosis and Therapy
Ischemic cardiovascular disease includes myocardial infarction, coronary atherosclerotic heart disease, angina pectoris, etc., constitute the leading cause of patient mortality by preventing tissues from getting sufficient oxygen and nutrients. Ischemic heart disease, as a clinical condition, is characterized by myocardial ischemia, causing an imbalance between myocardial blood supply and demand, ...read more
TREATMENT OF CARDIOVASCULAR DISEASE IN CHRONIC AND END STAGE KIDNEY DISEASE
Cardiovascular disease still remains the leading cause of death in Chronic and End Stage Kidney Disease, accounting for more than half of all deaths in dialysis patients. During the past decade, research has been focused on novel therapeutic agents that might delay or even reverse cardiovascular disease and vascular calcification, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Anti-VEGF Drugs in Eye Diseases: Local Therapy with Potential Systemic Effects
Current Pharmaceutical Design Markers of Systemic Inflammation in Obstructive Sleep Apnea Syndrome
Current Respiratory Medicine Reviews Mechanisms of Neurodegeration in Type 2 Diabetes and the Neuroprotective Potential of Dipeptidyl Peptidase 4 Inhibitors
Current Medicinal Chemistry microRNA as Biomarkers and Regulator of Cardiovascular Development and Disease
Current Pharmaceutical Design Activated Immune System and Inflammation in Healthy Ageing: Relevance for Tryptophan and Neopterin Metabolism
Current Pharmaceutical Design Late Effects in Survivors of Childhood CNS Tumors: Review of Results From the Two Largest Survivorship Cooperative Groups
Current Cancer Therapy Reviews Mitochondrial Disturbances, Tryptophan Metabolites and Neurodegeneration: Medicinal Chemistry Aspects
Current Medicinal Chemistry Hyperhomocysteinemia, Pteridines and Oxidative Stress
Current Drug Metabolism Applications of Arterial Spin Labelling in Mild Cognitive Impairment, Alzheimers Disease and Other Forms of Dementia
Current Medical Imaging Inhibitors of Serine Proteinases from Blood Coagulation Cascade - View on Current Developments
Mini-Reviews in Medicinal Chemistry The Triad: Erectile Dysfunction - Endothelial Dysfunction - Cardiovascular Disease
Current Pharmaceutical Design Patent Selections:
Recent Patents on Cardiovascular Drug Discovery Neuroprotective Efficacy of the Peroxisome Proliferator-Activated Receptor-γ Ligand in Chronic Cerebral Hypoperfusion
Current Neurovascular Research Update on Glycoprotein IIb/IIIa: Role in Primary Coronary Intervention
Cardiovascular & Hematological Agents in Medicinal Chemistry Insulin- and Growth Factor-Resistance Impairs Vascular Regeneration in Diabetes Mellitus
Current Vascular Pharmacology Overview and Findings from the Religious Orders Study
Current Alzheimer Research The Science of Hypoglycemia in Patients with Diabetes
Current Diabetes Reviews Microbial Biotransformation: Recent Developments on Steroid Drugs
Recent Patents on Biotechnology Oxidative Stress and Antioxidants in Hypertension–A Current Review
Current Hypertension Reviews Acute Phase Proteins In Acute Coronary Syndrome: An up-to-date
Cardiovascular & Hematological Agents in Medicinal Chemistry